Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Reports Third Quarter 2022 Financial Results
CNSide™ study data featured in three poster presentations at leading neuro-oncology annual meeting Participates in UCSF investigator-initiated study to better understand the development and progression of metastatic breast cancer to the central nervous system CNSide orders increased 8% over 2Q 2022
View HTML
Toggle Summary Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms.
View HTML
Toggle Summary Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
Conducted by leading breast oncologists from UCSF under a grant from the California Breast Cancer Research Program and the University of California , San Francisco Brain Spore, the study will analyze results from cerebrospinal fluid using Biocept’s CNSide™ assay with results from blood samples SAN
View HTML
Toggle Summary Biocept Reports Second Quarter 2022 Financial Results
Included first revenue from biopharma collaborator using CNSide™ in their therapeutics clinical trial First site opened for patient enrollment in the FORESEE trial to generate evidence of CNSide’s clinical utility Expanded the commercial availability of CNSide to metastatic melanoma CNSide™ orders
View HTML
Toggle Summary Biocept to Present at the LD Micro Main Event XV
SAN DIEGO --(BUSINESS WIRE)--Oct. 19, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at 2:30 p.m. Pacific time ( 5:30 p.m. Eastern time ).
View HTML
Toggle Summary Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
The cerebrospinal fluid (CSF) assay is now validated for melanomas and carcinomas, providing information to help physicians improve treatment decisions for more patients with advanced cancers SAN DIEGO --(BUSINESS WIRE)--Oct. 17, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
View HTML
Toggle Summary Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
Real-world case studies to be presented by leading neuro-oncologists Dr. Priya U. Kumthekar of Northwestern University and Dr. Seema A. Nagpal of Stanford University SAN DIEGO --(BUSINESS WIRE)--Oct. 14, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays,
View HTML
Toggle Summary Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
Presenters include leading neuro-oncologists Dr. Priya U. Kumthekar of Northwestern University and Dr. Seema A. Nagpal of Stanford University SAN DIEGO --(BUSINESS WIRE)--Oct. 6, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces
View HTML
Toggle Summary Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Aug. 31, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 89,550 shares of its common stock to 12 new employees.
View HTML
Toggle Summary Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q
SAN DIEGO --(BUSINESS WIRE)--Aug. 22, 2022-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the “Notice”) on August 17, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC
View HTML